Nektar Therapeutics (NKTR)

Market Cap	184.46M
Revenue (ttm)	93.14M
Net Income (ttm)	-168.30M
Shares Out	184.46M
EPS (ttm)	-0.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,476,216
Open	1.070
Previous Close	1.030
Day's Range	1.000 - 1.070
52-Week Range	0.420 - 1.930
Beta	0.61
Analysts	Buy
Price Target	4.00 (+300.0%)
Earnings Date	Nov 7, 2024

About NKTR

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applicatio...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 3, 1994
• Employees: 137
• Stock Exchange: NASDAQ
• Ticker Symbol: NKTR
• Website: https://www.nektar.com

Financial Performance

In 2023, Nektar Therapeutics's revenue was $90.12 million, a decrease of -2.10% compared to the previous year's $92.06 million. Losses were -$276.06 million, -25.03% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for NKTR stock is "Buy." The 12-month stock price forecast is $4.0, which is an increase of 300.00% from the latest price.

Price Target

$4.0

(300.00% upside)

Analyst Consensus: Buy